Literature DB >> 32936333

Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease.

Jad Chahoud1, Melissa McGettigan2, Nainesh Parikh2, Ronald S Boris3, Othon Iliopoulos4, W Kimryn Rathmell5, Anthony B Daniels6, Eric Jonasch7, Philippe E Spiess8.   

Abstract

This brief report focuses on the evaluation and diagnosis of clinically localized renal masses in children and adults with Von Hippel-Lindau (VHL) disease. Counseling considerations pertinent to the urologists, medical oncologists, and multidisciplinary teams involved in the care of these patients are addressed. As practice patterns regarding the evaluation and management of VHL tumors can vary considerably, this report aims to provide guidance on some of the controversies associated with the diagnostic evaluation and initial management of localized renal masses in VHL patients.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  RCC; Renal cell carcinoma; Renal mass; VHL; Von Hippel–Lindau

Year:  2020        PMID： 32936333      PMCID： PMC8101019          DOI： 10.1007/s00345-020-03441-3

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


  27 in total

1.  GRADE guidelines: 3. Rating the quality of evidence.

Authors:  Howard Balshem; Mark Helfand; Holger J Schünemann; Andrew D Oxman; Regina Kunz; Jan Brozek; Gunn E Vist; Yngve Falck-Ytter; Joerg Meerpohl; Susan Norris; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2011-01-05       Impact factor: 6.437

Review 2.  Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.

Authors:  Surya P Rednam; Ayelet Erez; Harriet Druker; Katherine A Janeway; Junne Kamihara; Wendy K Kohlmann; Katherine L Nathanson; Lisa J States; Gail E Tomlinson; Anita Villani; Stephan D Voss; Joshua D Schiffman; Jonathan D Wasserman
Journal:  Clin Cancer Res       Date:  2017-06-15       Impact factor: 12.531

3.  Survival and causes of death in patients with von Hippel-Lindau disease.

Authors:  Marie Louise Mølgaard Binderup; Annette Møller Jensen; Esben Budtz-Jørgensen; Marie Luise Bisgaard
Journal:  J Med Genet       Date:  2016-08-18       Impact factor: 6.318

Review 4.  von Hippel-Lindau disease: a clinical and scientific review.

Authors:  Eamonn R Maher; Hartmut Ph Neumann; Stéphane Richard
Journal:  Eur J Hum Genet       Date:  2011-03-09       Impact factor: 4.246

Review 5.  Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome.

Authors:  Sarah M Nielsen; Lindsay Rhodes; Ignacio Blanco; Wendy K Chung; Charis Eng; Eamonn R Maher; Stéphane Richard; Rachel H Giles
Journal:  J Clin Oncol       Date:  2016-04-25       Impact factor: 44.544

Review 6.  von Hippel-Lindau disease: genetic, clinical, and imaging features.

Authors:  P L Choyke; G M Glenn; M M Walther; N J Patronas; W M Linehan; B Zbar
Journal:  Radiology       Date:  1995-03       Impact factor: 11.105

Review 7.  VHL, the story of a tumour suppressor gene.

Authors:  Lucy Gossage; Tim Eisen; Eamonn R Maher
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 8.  A Review of Von Hippel-Lindau Syndrome.

Authors:  Neha Varshney; Amanuel A Kebede; Harry Owusu-Dapaah; Jason Lather; Manu Kaushik; Jasneet S Bhullar
Journal:  J Kidney Cancer VHL       Date:  2017-08-02

9.  Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma.

Authors:  Kenan Ashouri; Sophia Mohseni; John Tourtelot; Pranav Sharma; Philippe E Spiess
Journal:  J Kidney Cancer VHL       Date:  2015-09-25

Review 10.  Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.

Authors:  Eamonn R Maher
Journal:  World J Urol       Date:  2018-04-21       Impact factor: 4.226
View more
  5 in total

1.  Endolymphatic Sac Tumor Screening and Diagnosis in von Hippel-Lindau Disease: A Consensus Statement.

Authors:  Gautam U Mehta; H Jeffery Kim; Paul W Gidley; Anthony B Daniels; Mia E Miller; Gregory P Lekovic; John A Butman; Russell R Lonser
Journal:  J Neurol Surg B Skull Base       Date:  2021-04-08

Review 2.  MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.

Authors:  Elshad Hasanov; Eric Jonasch
Journal:  Expert Opin Investig Drugs       Date:  2021-05-20       Impact factor: 6.206

3.  Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service.

Authors:  Eamonn R Maher; Julian Adlard; Julian Barwell; Angela F Brady; Paul Brennan; Jackie Cook; Gillian S Crawford; Tabib Dabir; Rosemarie Davidson; Rebecca Dyer; Rachel Harrison; Claire Forde; Dorothy Halliday; Helen Hanson; Eleanor Hay; Jenny Higgs; Mari Jones; Fiona Lalloo; Zosia Miedzybrodzka; Kai Ren Ong; Frauke Pelz; Deborah Ruddy; Katie Snape; James Whitworth; Richard N Sandford
Journal:  Br J Cancer       Date:  2022-02-19       Impact factor: 9.075

4.  Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients.

Authors:  Kenan Zhang; Jianhui Qiu; Lin Cai; Kan Gong; Wuping Yang; Kaifang Ma; Lei Li; Haibiao Xie; Yawei Xu; Yanqing Gong; Jingcheng Zhou
Journal:  J Med Genet       Date:  2021-12-16       Impact factor: 5.941

5.  Multidisciplinary integrated care pathway for von Hippel-Lindau disease.

Authors:  Wendy P G Wolters; Koen M A Dreijerink; Rachel H Giles; Anouk N A van der Horst-Schrivers; Bernadette van Nesselrooij; Wouter T Zandee; Henri J L M Timmers; Tatjana Seute; Wouter W de Herder; Annemarie A Verrijn Stuart; Emine Kilic; Willem M Brinkman; Patricia J Zondervan; W Peter Vandertop; Anthony B Daniels; Tijmen Wolbers; Thera P Links; Rachel S van Leeuwaarde
Journal:  Cancer       Date:  2022-05-17       Impact factor: 6.921
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.